Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: A new therapeutic strategy for Alzheimer's disease

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Wood, Paul L ^a   Smith, Tara ^b   Lane, Nina ^b   Khan, M Amin ^b   Ehrmantraut, Greg ^b   Goodenowe, Dayan B ^b  

^a Lincoln Memorial University   (United States)

^b Phenomenome Discoveries Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; DOCOSAHEXAENOIC ACID; GLYCEROL; PALMITIC ACID; PHOSPHATIDYLETHANOLAMINE; PLASMALOGEN; PPI 1011; THIOCTIC ACID; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; DIACYLGLYCEROL; GLYCEROPHOSPHOETHANOLAMINE; HEXANOIC ACID DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG PENETRATION; FEMALE; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PLASMA; RABBIT; ANIMAL; BIOAVAILABILITY; BLOOD; DRUG SCREENING; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ORYCTOLAGUS CUNICULUS;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AVAILABILITY; DIGLYCERIDES; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HEXANOIC ACIDS; PHOSPHATIDYLETHANOLAMINES; PLASMALOGENS; RABBITS; TISSUE DISTRIBUTION;

EID: 82655180641     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-227     Document Type: Article

References (41)

1. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A, Ann Neurol 1988 23 138 44 10.1002/ana.410230206 2897823 (Pubitemid 18081451)
2. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC, Arch Neurol 2005 62 758 65 10.1001/archneur.62.5.758 15883263 (Pubitemid 40656091)
3. Neuropathology of older persons without cognitive impairment from two community-based studies. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS, Neurology 2006 66 1837 44 10.1212/01.wnl. 0000219668.47116.e6 16801647 (Pubitemid 44049813)
4. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. de la Monte SM, Ann Neurol 1989 25 450 9 10.1002/ana.410250506 2774485 (Pubitemid 19136675)
5. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH, Br Med J 1978 25 1457 9 (Pubitemid 9061468)
6. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. Wilcock GK, Esiri MM, Bowen DM, Smith CC, J Neurol Sci 1982 57 407 17 10.1016/0022-510X(82)90045-4 7161627 (Pubitemid 13212275)
7. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Burns JM, Church JA, Johnson DK, Xiong C, Marcus D, Fotenos AF, Snyder AZ, Morris JC, Buckner RL, Arch Neurol 2005 62 1870 6 10.1001/archneur.62.12.1870 16344345 (Pubitemid 41785081)
8. Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy? de Leeuw FE, Barkhof F, Scheltens P, J Neurol Neurosurg Psychiatry 2005 76 1286 8 10.1136/jnnp.2004.053686 16107369 (Pubitemid 41208386)
9. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. de Leeuw FE, Korf E, Barkhof F, Scheltens P, Stroke 2006 37 2248 52 10.1161/01.STR.0000236555.87674.e1 16902173 (Pubitemid 44337164)
10. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M, Koshino Y, Neuropathol Appl Neurobiol 2002 28 238 51 10.1046/j.1365-2990.2002.00390.x 12060348 (Pubitemid 34639446)
11. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Perry RH, Candy JM, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE, Neurosci Lett 1982 33 311 10.1016/0304-3940(82)90391-3 7162693 (Pubitemid 13119540)
12. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Pearson RC, Sofroniew MV, Cuello AC, Powell TP, Eckenstein F, Esiri MM, Wilcock GK, Brain Res 1983 289 375 9 10.1016/0006-8993(83)90046-X 6362777 (Pubitemid 14222546)
13. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Vogels OJ, Broere CA, ter Laak HJ, ten Donkelaar HJ, Nieuwenhuys R, Schulte BP, Neurobiol Aging 1990 11 3 13 10.1016/0197-4580(90) 90056-6 2183081 (Pubitemid 20097854)
14. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Etienne P, Robitaille Y, Wood P, Gauthier S, Nair NP, Quirion R, Neuroscience 1986 19 1279 91 10.1016/0306-4522(86)90142-9 3822122 (Pubitemid 17217023)
15. Amygdala cell loss and atrophy in Alzheimer's disease. Scott SA, DeKosky ST, Sparks DL, Knox CA, Scheff SW, Ann Neurol 1992 32 555 63 10.1002/ana.410320412 1456740
16. Measuring morphological and cellular changes in Alzheimer's dementia: a review emphasizing stereology. Stark AK, Pelvig DP, Jørgensen AM, Andersen BB, Pakkenberg B, Curr Alzheimer Res 2005 2 449 81 10.2174/ 156720505774330528 16248850 (Pubitemid 41277759)
17. Quantitative estimations of the entorhinal cortex in Alzheimer's disease. Artacho-Pérula E, Insausti R, Anal Quant Cytol Histol 2007 29 1 16 17375870 (Pubitemid 46333517)
18. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, Leahy M, Montine T, Kaye J, Neurology 2009 72 354 60 10.1212/01.wnl.0000341273.18141.64 19171833
19. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL, Brain Res 1995 698 223 6 10.1016/0006-8993(95)00931-F 8581486
20. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Farooqui AA, Rapoport SI, Horrocks LA, Neurochem Res 1997 22 523 7 10.1023/A:1027380331807 9130265 (Pubitemid 27184719)
21. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ, J Neuropathol Exp Neurol 1999 58 740 7 10.1097/00005072-199907000-00008 10411344 (Pubitemid 29328503)
22. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. Han X, Holtzman DM, McKeel DW Jr, J Neurochem 2001 77 1168 80 10.1046/j.1471-4159.2001.00332.x 11359882 (Pubitemid 32467071)
23. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Scott BL, Bazan NG, Proc Natl Acad Sci USA 1989 86 2903 7 10.1073/pnas.86.8.2903 2523075 (Pubitemid 19112648)
24. Deficient liver biosynthesis of docosahexaenoic Acid correlates with cognitive impairment in Alzheimer's disease. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D, PLoS One 2010 5 12538 10.1371/journal.pone.0012538 20838618
25. Peroxisomal alterations in Alzheimer's disease. Kou J, Kovacs GG, Höftberger R, Kulik W, Brodde A, Forss-Petter S, Hönigschnabl S, Gleiss A, Brügger B, Wanders R, Just W, Budka H, Jungwirth S, Fischer P, Berger J, Acta Neuropathol 2011 122 271 83 10.1007/s00401-011-0836-9 21594711
26. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL, J Lipid Res 2007 48 2485 98 10.1194/jlr.P700023-JLR200 17664527 (Pubitemid 350058760)
27. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, Goodenowe DB, J Psychiatry Neurosci 2010 35 59 62 10.1503/jpn.090059 20040248
28. Plasmalogen deficit: A new and testable hypothesis for the etiology of Alzheimer's disease. Wood PL, Khan MA, Mankidy R, Smith T, Goodenowe DB, Alzheimer's Disease/Book 2 2011 ISBN 979-953-307-022-2 22146778
29. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W, Braverman NE, Goodenowe DB, Lipids Health Dis 2011 10 182 22008564
30. Delivery of substances to the rabbit gastrointestinal tract by oral dosing with gelatin capsules. Eng LA, Carrig CB, Cordle CT, Metz CB, Lab Anim Sci 1987 37 239 41 3599900
31. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. Teichert J, Hermann R, Ruus P, Preiss R, J Clin Pharmacol 2003 43 1257 67 10.1177/0091270003258654 14551180 (Pubitemid 37280797)
32. Direct synthesis of plasmenylcholine from allyl-substituted glycerols. Shin J, Thompson DH, J Org Chem 2003 68 6760 6 10.1021/jo026826w 12919045 (Pubitemid 37010987)
33. Molecular identification of a novel mammalian brain isoform of acyl-CoA:lysophospholipid acyltransferase with prominent ethanolamine lysophospholipid acylating activity, LPEAT2. Cao J, Shan D, Revett T, Li D, Wu L, Liu W, Tobin JF, Gimeno RE, J Biol Chem 2008 283 19049 57 10.1074/jbc.M800364200 18458083
34. Acyl-CoA:lysophospholipid acyltransferases. Shindou H, Shimizu T, J Biol Chem 2009 284 1 5 18718904
35. Studies on plasmalogen-selective phospholipase A2 in brain. Farooqui AA, Mol Neurobiol 2010 41 267 73 10.1007/s12035-009-8091-y 20049656
36. Metabolism of the enantiomeric I-O-alkyl glycerol ethers in the rat intestinal mucosa in vivo; incorporation into I-O-alkyl and I-O-alk-I'-enyl glycerol lipids. Paltauf F, Biochim Biophys Acta 1971 239 38 46 5569939
37. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G, J Lipid Res 2009 50 574 85 18832345
38. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro. Candela P, Gosselet F, Miller F, Buee-Scherrer V, Torpier G, Cecchelli R, Fenart L, Endothelium 2008 15 254 64 10.1080/10623320802487759 19065317
39. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R, J Cell Biol 1997 138 877 89 10.1083/jcb.138.4.877 9265653 (Pubitemid 27365049)
40. Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins. Polozova A, Gionfriddo E, Salem N Jr, Prostaglandins Leukot Essent Fatty Acids 2006 75 183 90 10.1016/j.plefa.2006.05.009 16837179 (Pubitemid 44292522)
41. Mechanisms of action of docosahexaenoic acid in the nervous system. Salem N Jr, Litman B, Kim HY, Gawrisch K, Lipids 2001 36 945 59 10.1007/s11745-001- 0805-6 11724467 (Pubitemid 33065196)